» Articles » PMID: 16150490

Pharmaceutical Cost Management and Access to Psychotropic Drugs: the U.S. Context

Overview
Publisher Elsevier
Date 2005 Sep 10
PMID 16150490
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

In recent years, prescription drug expenditures in the United States have increased rapidly. In 2003, spending on prescription medications totaled $179.2 billion dollars, or approximately 11% of national health expenditures [Smith, C., Cowan, C., Sensenig, A., Catlin, A., the Health Accounts Team. (2005). Health spending growth slows in 2003. Health Affairs, 24 (1) 185-194]. In response to rapid increases in prescription drug expenditures, both public and private payers of health care services have adopted strategies to try to contain drug costs, including drug formularies, prior authorization programs, cost sharing and utilization management. In this paper, I provide a background on prescription drug spending trends, financing, and access to medications; describe some of the tools used most commonly to manage prescription drug utilization; present results from the literature on the impact of these tools; and discuss some implications of this information for the new Medicare prescription drug benefit to be implemented in 2006 as well as for future prescription drug innovation.

Citing Articles

Treatment patterns and hospitalizations following rejection, reversal, or payment of the initial once-monthly paliperidone palmitate long-acting injectable antipsychotic claim among patients with schizophrenia or schizoaffective disorder.

Benson C, Patel C, Lee I, Shaikh N, Wang Y, Zhao X J Manag Care Spec Pharm. 2024; 30(9):954-966.

PMID: 38831661 PMC: 11365566. DOI: 10.18553/jmcp.2024.23252.


Stability of the Inclusion Complexes of Dodecanoic Acid with α-Cyclodextrin, β-Cyclodextrin and 2-HP-β-Cyclodextrin.

Kinart Z Molecules. 2023; 28(7).

PMID: 37049876 PMC: 10095696. DOI: 10.3390/molecules28073113.


Factors Associated With Off-Label Utilization of Second-Generation Antipsychotics Among Publicly Insured Adults.

Horvitz-Lennon M, Volya R, Hollands S, Zelevinsky K, Mulcahy A, Donohue J Psychiatr Serv. 2021; 72(9):1031-1039.

PMID: 34074139 PMC: 8410611. DOI: 10.1176/appi.ps.202000381.


Trends in the access to and the use of antipsychotic medications and psychotropic co-treatments in Asian patients with schizophrenia.

Xiang Y, Ungvari G, Correll C, Chiu H, Shinfuku N Epidemiol Psychiatr Sci. 2015; 25(1):9-17.

PMID: 26289066 PMC: 6998674. DOI: 10.1017/S2045796015000694.


Management of newer medications for attention-deficit/hyperactivity disorder in commercial health plans.

Hodgkin D, Horgan C, Quinn A, Merrick E, Stewart M, Leslie L Clin Ther. 2014; 36(12):2034-2046.

PMID: 25450473 PMC: 4282778. DOI: 10.1016/j.clinthera.2014.09.019.


References
1.
Frank R . Prescription drug prices: why do some pay more than others do?. Health Aff (Millwood). 2001; 20(2):115-28. DOI: 10.1377/hlthaff.20.2.115. View

2.
Motheral B, Fairman K . Effect of a three-tier prescription copay on pharmaceutical and other medical utilization. Med Care. 2001; 39(12):1293-304. DOI: 10.1097/00005650-200112000-00005. View

3.
Simon G . Choosing a first-line antidepressant: equal on average does not mean equal for everyone. JAMA. 2001; 286(23):3003-4. DOI: 10.1001/jama.286.23.3003. View

4.
Joyce G, Escarce J, Solomon M, Goldman D . Employer drug benefit plans and spending on prescription drugs. JAMA. 2002; 288(14):1733-9. DOI: 10.1001/jama.288.14.1733. View

5.
Zito J, Safer D, dosReis S, Gardner J, Magder L, Soeken K . Psychotropic practice patterns for youth: a 10-year perspective. Arch Pediatr Adolesc Med. 2003; 157(1):17-25. DOI: 10.1001/archpedi.157.1.17. View